Clinical Trials Logo

Premature Birth clinical trials

View clinical trials related to Premature Birth.

Filter by:

NCT ID: NCT04037514 Recruiting - Clinical trials for Patent Ductus Arteriosus After Premature Birth

Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus

IBUPAR
Start date: July 7, 2017
Phase: Phase 3
Study type: Interventional

Multicentric, double-blind clinical trial, which will evaluate the efficacy of iv paracetamol versus standard treatment with ibuprofen in the closure of patent ductus arteriosus in the preterm newborn. Secondarily, we intend to compare the safety of both treatments, increase our knowledge about the pharmacokinetics, pharmacodynamics and pharmacogenetics of paracetamol and ibuprofen in the neonatal period and make a pharmacoeconomic assessment of the use of both drugs.

NCT ID: NCT04031456 Recruiting - Clinical trials for Premature Ovarian Failure

Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients

PRP
Start date: July 30, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.

NCT ID: NCT04025177 Withdrawn - Clinical trials for Patent Ductus Arteriosus After Premature Birth

Indomethacin PK-PD in Extremely Preterm Neonates

INDO
Start date: January 2020
Phase: Phase 2
Study type: Interventional

This is a phase II open-label study evaluating the pharmacokinetics and pharmacodynamics of targeted early use of indomethacin for PDA treatment in preterm neonates <27 weeks' gestational age.

NCT ID: NCT04021654 Completed - Preterm Birth Clinical Trials

What is the Future of Vulnerable New-borns

DNNV
Start date: September 1, 2018
Phase:
Study type: Observational

The aim of this data base is to know exactly the future of a "vulnerable newborns" cared in Pontoise Hospital (In the neonatology service) and compare the information with the national data of preterm birth.

NCT ID: NCT04021485 Recruiting - Clinical trials for Premature Childbirth

BETAmethasone Dose Reduction: Non-Inferiority on the Neurocognitive Outcomes of Children Born Before 32 Weeks of Gestation

BETANINO
Start date: March 23, 2022
Phase: N/A
Study type: Interventional

Maternal antenatal corticosteroid therapy is the last major advance in the antenatal management of fetuses to prevent neonatal complications associated with prematurity. Long-term neurological outcomes in infants exposed to antenatal steroids have been assessed in few cohorts and suggest that this therapy is able to prevent some neurodevelopmental impairments including cerebral palsy. While >85% of neonates born very preterm in Europe have been exposed to antenatal betamethasone, Cochrane collaborative networks stated that trials of dosages comparing different regimens of commonly used corticosteroids are most urgently needed to avoid useless fetal exposure to excessive dosage of corticosteroids. - Because a half dosage was associated with maximal benefits on lung function in ewes, a randomized controlled trial (BETADOSE, NCT02897076) has been conducted to demonstrate that a 50% reduced betamethasone dose regimen is not inferior to a full dose to prevent respiratory distress syndrome in preterm neonates. BETADOSE trial demonstrated that half dose did not show noninferiority to full antenatal betamethasone dose regimen to prevent severe RDS in preterm neonates while other prematurity-associated complications, including those usually prevented by ACS, did not differ between the two groups. - Results of the 5-year BETANINO follow-up study of the BETADOSE neonates are needed before deciding whether reducing ACS dose is possible The main hypothesis of BETANINO is that half dose regimen of betamethasone is not inferior to full dose regimen of betamethasone to prevent neurodevelopmental impairments in these high-risk children born very preterm at 5 years of age.

NCT ID: NCT04015180 Active, not recruiting - Clinical trials for Retinopathy of Prematurity (ROP)

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

FIREFLEYE next
Start date: March 18, 2020
Phase: Phase 3
Study type: Interventional

This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.

NCT ID: NCT04012437 Completed - Clinical trials for Premature Ejaculation

Efficacy of App and Electronic Device in the Treatment of Premature Ejaculation

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Randomized control trial to determine if we can produce increases in the IELT using a new masturbator electronic in subjects with premature ejaculation in combination with a exercise app, producing improvements in the quality and satisfaction of the sexuality of the patient.

NCT ID: NCT04009655 Completed - Preterm Infant Clinical Trials

The Effects of Music Therapy on Near-infrared Spectroscopy and Electroencephalogram in Premature Infants

Start date: August 15, 2019
Phase: N/A
Study type: Interventional

Music has been consistently shown magic power in brain plasticity. Several study proved music can influence electronic activity of preterm infants' brain, while none study covered region oxygen metabolic. The investigators aim to discover the effects of music therapy on near-infrared spectroscopy and electroencephalogram in premature infants.

NCT ID: NCT04009473 Enrolling by invitation - Menopause Clinical Trials

Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation

SEGOVA
Start date: June 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.

NCT ID: NCT04008498 Completed - Preterm Infant Clinical Trials

AEEG in Pre-term Infants

AEEG
Start date: May 30, 2018
Phase: N/A
Study type: Interventional

Amplitude integrated encephalography (aEEG) is a monitor that measures brain activity by attaching leads to a baby's head, and is used routinely in term babies who have brain injury because of a difficult birth. There is little information on how useful aEEG is in premature babies, and most studies only look at small numbers of babies. However, these studies suggest that the aEEG is different in premature babies with brain injury, infections / meningitis, and in those receiving certain drugs. It is also affected by changes in blood pressure and blood acid levels. It is theoretically possible that, if the investigators can detect changes using aEEG early on, the investigators will be able adjust treatment to make a baby better.